Common use of RIGHT TO INFORMATION Clause in Contracts

RIGHT TO INFORMATION. Each one of the PARTIES is informed that the professional contact details will be processed by the other party for the purpose of managing this contract, with the basis for processing being its execution. The data will be stored during the time that the contractual relationship lasts and until the eventual liabilities arising from it have lapsed. Furthermore, the PARTIES will not assign the data to third parties, except where there is a legal obligation to do so. Moreover, the PARTIES may, at any time, exercise their right of access, rectification, restriction, erasure, objection and portability with respect to their personal data, by writing to the PARTIES’ data protection officers: Data protection officers’ contact details for all the PARTIES: HOSPITAL: Contact: Comité DPD de la Consejería de Sanidad de la Comunidad de Madrid Address: Xxxxx Xxxxxx Xxxxx Xxxxxxx nº 7 (Edif. Sollube) Madrid 28020 FOUNDATION: Contact: Xxxxx Xxxxx, S.L. xxx.xxxxxxxxxxxxxxxxxxx@xxxxxxxxxx.xxx Address: Xxxx. xx Xxxxxx 00, 0X, 00000, Xxxxxx SPONSOR : Contact :_________________________________ Address: ___________________________________ The PARTIES may also submit a claim to the Spanish Data Protection Agency: If one of the PARTIES wishes to transfer the signatories’ Personal Data outside the European Economic Area (EEA) or Switzerland, this may only be done where permitted by the applicable legislation in the EEA, based on the legal mechanisms for transfer or with prior authorisation from the other PARTIES affected. EIGHT. INVESTIGATIONAL PRODUCTS 8.1. The SPONSOR will supply the medical device on research free-of-charge, including those for comparison ,under the terms provided for in RD1090/2015. 8.2. The investigational medicinal product will be supplied via the HOSPITAL’s ______________Department and dispensed on a controlled basis, in accordance with the guidelines in the PROTOCOL. 8.3. The drug on research will not be made available to the HOSPITAL or the PRINCIPAL INVESTIGATOR until the favourable report from the CEIm and the mandatory authorisation from the AEMPS are received.

RIGHT TO INFORMATION. Each one of the PARTIES is informed that the professional contact details will be processed by the other party for the purpose of managing this contract, with the basis for processing being its execution. The data will be stored during the time that the contractual relationship lasts and until the eventual liabilities arising from it have lapsed. Furthermore, the PARTIES will not assign the data to third parties, except where there is a legal obligation to do so. Moreover, the PARTIES may, at any time, exercise their right of access, rectification, restriction, erasure, objection and portability with respect to their personal data, by writing to the PARTIES’ data protection officers: Data protection officers’ contact details for all the PARTIES: HOSPITAL: Contact: Comité DPD de la Consejería de Sanidad de la Comunidad de Madrid Address: Xxxxx Xxxxxx Xxxxx Xxxxxxx nº 7 (Edif. Sollube) Madrid 28020 FOUNDATION: Contact: Xxxxx Xxxxx, S.L. xxx.xxxxxxxxxxxxxxxxxxx@xxxxxxxxxx.xxx Address: Xxxx. xx Xxxxxx 00, 0X, 00000, Xxxxxx SPONSOR : Contact :_________________________________ Address: ___________________________________ The PARTIES may also submit a claim to the Spanish Data Protection Agency: If one of the PARTIES wishes to transfer the signatories’ Personal Data outside the European Economic Area (EEA) or Switzerland, this may only be done where permitted by the applicable legislation in the EEA, based on the legal mechanisms for transfer or with prior authorisation from the other PARTIES affected. EIGHT. INVESTIGATIONAL MEDICINAL PRODUCTS 8.1. The SPONSOR will supply the medical device on research investigational medicinal products free-of-charge, including those for comparison ,and placebos, under the terms provided for in RD1090/2015. 8.2. The investigational medicinal product will be supplied via the HOSPITAL’s ______________Pharmacy Department and dispensed on a controlled basis, in accordance with the guidelines in the PROTOCOL. 8.3. The drug on research will not be made available to the HOSPITAL or the PRINCIPAL INVESTIGATOR until the favourable report from the CEIm and the mandatory authorisation from the AEMPS are received.

RIGHT TO INFORMATION. Each one of the PARTIES is informed that the professional contact details will be processed by the other party for the purpose of managing this contract, with the basis for processing being its execution. The data will be stored during the time that the contractual relationship lasts and until the eventual liabilities arising from it have lapsed. Furthermore, the PARTIES will not assign the data to third parties, except where there is a legal obligation to do so. Moreover, the PARTIES may, at any time, exercise their right of access, rectification, restriction, erasure, objection and portability with respect to their personal data, by writing to the PARTIES’ data protection officers: Data protection officers’ contact details for all the PARTIES: HOSPITAL: Contact: Comité DPD de la Consejería de Sanidad de la Comunidad de Madrid Address: Xxxxx Xxxxxx Xxxxx Xxxxxxx nº 7 (Edif. Sollube) Madrid 28020 Mail: xxxxxxxxxxxxxxxxx.xxxxxxx@xxxxxx.xxx FOUNDATION: ContactContact : Xxxxx Xxxxx, SEGURDADES S.L. xxx.xxxxxxxxxxxxxxxxxxx@xxxxxxxxxx.xxx Address: Xxxx. xx Xxxxxx 00X/ Xxxxxxxx, 0X6 (43800 – Valls, 00000, Xxxxxx Tarragona) mail: xxx@xxxxxxxxxx.xxx SPONSOR : Contact :_________________________________ Address: ___________________________________ The PARTIES may also submit a claim to the Spanish Data Protection Agency: If one of the PARTIES wishes to transfer the signatories’ Personal Data outside the European Economic Area (EEA) or Switzerland, this may only be done where permitted by the applicable legislation in the EEA, based on the legal mechanisms for transfer or with prior authorisation from the other PARTIES affected. EIGHT. INVESTIGATIONAL MEDICINAL PRODUCTS 8.1. The SPONSOR will supply the medical device on research investigational medicinal products free-of-charge, including those for comparison ,and placebos, under the terms provided for in RD1090/2015. 8.2. The investigational medicinal product will be supplied via the HOSPITAL’s ______________Pharmacy Department and dispensed on a controlled basis, in accordance with the guidelines in the PROTOCOL. 8.3. The drug on research will not be made available to the HOSPITAL or the PRINCIPAL INVESTIGATOR until the favourable report from the CEIm and the mandatory authorisation from the AEMPS are received.

RIGHT TO INFORMATION. Each one of the PARTIES is informed that the professional contact details will be processed by the other party for the purpose of managing this contract, with the basis for processing being its execution. The data will be stored during the time that the contractual relationship lasts and until the eventual liabilities arising from it have lapsed. Furthermore, the PARTIES will not assign the data to third parties, except where there is a legal obligation to do so. Moreover, the PARTIES may, at any time, exercise their right of access, rectification, restriction, erasure, objection and portability with respect to their personal data, by writing to the PARTIES’ data protection officers: Data protection officers’ contact details for all the PARTIES: HOSPITAL: Contact: Comité DPD de la Consejería de Sanidad de la Comunidad de Madrid Address: Xxxxx Xxxxxx Xxxxx Xxxxxxx nº 7 (Edif. Sollube) Madrid 28020 FOUNDATION: ContactContact : Xxxxx Xxxxx, SEGURDADES S.L. xxx.xxxxxxxxxxxxxxxxxxx@xxxxxxxxxx.xxx Address: Xxxx. xx Xxxxxx 00X/ Xxxxxxxx, 0X6 (43800 – Valls, 00000, Xxxxxx Tarragona) mail: xxx@xxxxxxxxxx.xxx SPONSOR : Contact :_________________________________ Address: ___________________________________ The PARTIES may also submit a claim to the Spanish Data Protection Agency: If one of the PARTIES wishes to transfer the signatories’ Personal Data outside the European Economic Area (EEA) or Switzerland, this may only be done where permitted by the applicable legislation in the EEA, based on the legal mechanisms for transfer or with prior authorisation from the other PARTIES affected. EIGHT. INVESTIGATIONAL MEDICINAL PRODUCTS 8.1. The SPONSOR will supply the medical device on research investigational medicinal products free-of-charge, including those for comparison ,and placebos, under the terms provided for in RD1090/2015. 8.2. The investigational medicinal product will be supplied via the HOSPITAL’s ______________Pharmacy Department and dispensed on a controlled basis, in accordance with the guidelines in the PROTOCOL. 8.3. The drug on research will not be made available to the HOSPITAL or the PRINCIPAL INVESTIGATOR until the favourable report from the CEIm and the mandatory authorisation from the AEMPS are received.

RIGHT TO INFORMATION. Each one of the PARTIES is informed that the professional contact details will be processed by the other party for the purpose of managing this contract, with the basis for processing being its execution. The data will be stored during the time that the contractual relationship lasts and until the eventual liabilities arising from it have lapsed. Furthermore, the PARTIES will not assign the data to third parties, except where there is a legal obligation to do so. Moreover, the PARTIES may, at any time, exercise their right of access, rectification, restriction, erasure, objection and portability with respect to their personal data, by writing to the PARTIES’ data protection officers: Data protection officers’ contact details for all the PARTIES: HOSPITAL: Contact: Comité DPD de la Consejería de Sanidad de la Comunidad de Madrid Address: Xxxxx Xxxxxx Xxxxx Xxxxxxx nº 7 (Edif. Sollube) Madrid 28020 FOUNDATION: Contact: Xxxxx Xxxxx, S.L. xxx.xxxxxxxxxxxxxxxxxxx@xxxxxxxxxx.xxx Address: Xxxx. xx Xxxxxx 00, 0X, 00000, Xxxxxx xxx.xxxxxxxxxxxxxxxxxxx@xxxxxxxxxx.xxx SPONSOR : Contact :_________________________________ Address: ___________________________________ The PARTIES may also submit a claim to the Spanish Data Protection Agency: If one of the PARTIES wishes to transfer the signatories’ Personal Data outside the European Economic Area (EEA) or Switzerland, this may only be done where permitted by the applicable legislation in the EEA, based on the legal mechanisms for transfer or with prior authorisation from the other PARTIES affected. EIGHTIn Witness Whereof, as proof of consent, all Parties sign this document in triplicate for this sole purpose Por el HOSPITAL / On behalf of HOSPITAL D. Xxxxx Xxxxxx Xxxxx Xxxxx Director Gerente Por la FUNDACIÓN / On behalf of FOUNDATION D. Xxxxx Xxxxxx Xxxxx Xxxxx Presidente Revisión previa y conforme, D. Xxxxx Xxxxxxxx Xxxxxxx Directora de la FIBHCSC En nombre del promotor /By and on behalf of Sponsor D./Dña. INVESTIGATIONAL PRODUCTS 8.1Investigador Principal /Principal Investigator Dr./Dra. El Investigador Principal comunicará por escrito a la FUNDACIÓN cualquier modificación en el equipo investigador. The SPONSOR will supply Principal Investigator shall notify the medical device on research free-of-charge, including those for comparison ,under the terms provided for FOUNDATION in RD1090/2015. 8.2. The investigational medicinal product will be supplied via the HOSPITAL’s ______________Department and dispensed on a controlled basis, in accordance with the guidelines writing of any modifications in the PROTOCOL. 8.3. The drug on research will not be made available to the HOSPITAL or the PRINCIPAL INVESTIGATOR until the favourable report from the CEIm and the mandatory authorisation from the AEMPS are receivedinvestigation team.

RIGHT TO INFORMATION. Each one of the PARTIES is informed that the professional contact details will be processed by the other party for the purpose of managing this contract, with the basis for processing being its execution. The data will be stored during the time that the contractual relationship lasts and until the eventual liabilities arising from it have lapsed. Furthermore, the PARTIES will not assign the data to third parties, except where there is a legal obligation to do so. Moreover, the PARTIES may, at any time, exercise their right of access, rectification, restriction, erasure, objection and portability with respect to their personal data, by writing to the PARTIES’ data protection officers: Data protection officers’ contact details for all the PARTIES: HOSPITAL: Contact: Comité DPD de la Consejería de Sanidad de la Comunidad de Madrid Address: Xxxxx Xxxxxx Xxxxx Xxxxxxx nº 7 (Edif. Sollube) Madrid 28020 Mail: xxxxxxxxxxxxxxxxx.xxxxxxx@xxxxxx.xxx FOUNDATION: ContactContact : Xxxxx Xxxxx, SEGURDADES S.L. xxx.xxxxxxxxxxxxxxxxxxx@xxxxxxxxxx.xxx Address: Xxxx. xx Xxxxxx 00X/ Xxxxxxxx, 0X6 (43800 – Valls, 00000, Xxxxxx Tarragona) mail: xxx@xxxxxxxxxx.xxx SPONSOR : Contact :_________________________________ Address: ___________________________________ The PARTIES may also submit a claim to the Spanish Data Protection Agency: If one of the PARTIES wishes to transfer the signatories’ Personal Data outside the European Economic Area (EEA) or Switzerland, this may only be done where permitted by the applicable legislation in the EEA, based on the legal mechanisms for transfer or with prior authorisation from the other PARTIES affected. EIGHT. INVESTIGATIONAL PRODUCTS MEDICAL DEVICES 8.1. The SPONSOR will supply the investigational medical device on research free-of-charge, including those for comparison ,comparison, under the terms provided for in RD1090/2015. 8.2. The investigational medicinal product medical device will be supplied via the HOSPITAL’s ___________________ Department and dispensed on a controlled basis, in accordance with the guidelines in the PROTOCOL. 8.3. The drug medical device on research will not be made available to the HOSPITAL or the PRINCIPAL INVESTIGATOR until the favourable report from the CEIm and the mandatory authorisation from the AEMPS (si aplica) are received.

RIGHT TO INFORMATION. Each one of the PARTIES is informed that the professional contact details will be processed by the other party for the purpose of managing this contract, with the basis for processing being its execution. The data will be stored during the time that the contractual relationship lasts and until the eventual liabilities arising from it have lapsed. Furthermore, the PARTIES will not assign the data to third parties, except where there is a legal obligation to do so. Moreover, the PARTIES may, at any time, exercise their right of access, rectification, restriction, erasure, objection and portability with respect to their personal data, by writing to the PARTIES’ data protection officers: Data protection officers’ contact details for all the PARTIES: HOSPITAL: Contact: Comité DPD de la Consejería de Sanidad de la Comunidad de Madrid Address: Xxxxx Xxxxxx Xxxxx Xxxxxxx nº 7 (Edif. Sollube) Madrid 28020 FOUNDATION: Contact: Xxxxx Xxxxx, S.L. xxx.xxxxxxxxxxxxxxxxxxx@xxxxxxxxxx.xxx Address: Xxxx. xx Xxxxxx 00, 0X, 00000, Xxxxxx xxx.xxxxxxxxxxxxxxxxxxx@xxxxxxxxxx.xxx SPONSOR : Contact :_________________________________ Address: ___________________________________ The PARTIES may also submit a claim to the Spanish Data Protection Agency: If one of the PARTIES wishes to transfer the signatories’ Personal Data outside the European Economic Area (EEA) or Switzerland, this may only be done where permitted by the applicable legislation in the EEA, based on the legal mechanisms for transfer or with prior authorisation from the other PARTIES affected. EIGHT. INVESTIGATIONAL PRODUCTS 8.1. The SPONSOR will supply the medical device In Witness Whereof, as proof of consent, all Parties sign this document in triplicate for this sole purpose POR LA FUNDACIÓN Y EL HOSPITAL/ FOR THE FOUNDATION AND THE HOSPITAL Fdo/Signed.: Mr. Xxxx Xxxxxxxxx Xxxx Xxxxx POR LA FUNDACIÓN /FOR THE FOUNDATION Fdo/Signed: Mrs. Xxxxx Xxxxxxxx Xxxxxxx En nombre del promotor /By and on research free-of-charge, including those for comparison ,under the terms provided for in RD1090/2015. 8.2. The investigational medicinal product will be supplied via the HOSPITAL’s ______________Department and dispensed on behalf of Sponsor Investigador Principal /Principal Investigator El Investigador Principal comunicará por escrito a controlled basis, in accordance with the guidelines in the PROTOCOL. 8.3. The drug on research will not be made available to the HOSPITAL or the PRINCIPAL INVESTIGATOR until the favourable report from the CEIm and the mandatory authorisation from the AEMPS are receivedla FUNDACIÓN cualquier modificación en el equipo investigador.

RIGHT TO INFORMATION. Each one of the PARTIES is informed that the professional contact details will be processed by the other party for the purpose of managing this contract, with the basis for processing being its execution. The data will be stored during the time that the contractual relationship lasts and until the eventual liabilities arising from it have lapsed. Furthermore, the PARTIES will not assign the data to third parties, except where there is a legal obligation to do so. Moreover, the PARTIES may, at any time, exercise their right of access, rectification, restriction, erasure, objection and portability with respect to their personal data, by writing to the PARTIES’ data protection officers: Data protection officers’ contact details for all the PARTIES: HOSPITAL: Contact: Comité DPD de la Consejería de Sanidad de la Comunidad de Madrid Address: Xxxxx Xxxxxx Xxxxx Xxxxxxx nº 7 (Edif. Sollube) Madrid 28020 FOUNDATION: ContactContact : Xxxxx Xxxxx, SEGURDADES S.L. xxx.xxxxxxxxxxxxxxxxxxx@xxxxxxxxxx.xxx Address: Xxxx. xx Xxxxxx 00X/ Xxxxxxxx, 0X6 (43800 – Valls, 00000, Xxxxxx Tarragona) mail: xxx@xxxxxxxxxx.xxx SPONSOR : Contact :_________________________________ Address: ___________________________________ The PARTIES may also submit a claim to the Spanish Data Protection Agency: If one of the PARTIES wishes to transfer the signatories’ Personal Data outside the European Economic Area (EEA) or Switzerland, this may only be done where permitted by the applicable legislation in the EEA, based on the legal mechanisms for transfer or with prior authorisation from the other PARTIES affected. EIGHT. INVESTIGATIONAL PRODUCTS MEDICAL DEVICES 8.1. The SPONSOR will supply the investigational medical device on research free-of-charge, including those for comparison ,comparison, under the terms provided for in RD1090/2015. 8.2. The investigational medicinal product medical device will be supplied via the HOSPITAL’s ___________________ Department and dispensed on a controlled basis, in accordance with the guidelines in the PROTOCOL. 8.3. The drug medical device on research will not be made available to the HOSPITAL or the PRINCIPAL INVESTIGATOR until the favourable report from the CEIm and the mandatory authorisation from the AEMPS (si aplica) are received.